Inhibition of human leukocyte elastase activity by chondroitin sulfates

Chemico-Biological Interactions

Volumn 105, Issue 3, 1997, Pages 157-167

  Volpi, Nicola ^a  

^a UNIVERSITY OF MODENA AND REGGIO EMILIA   (Italy)

Author keywords

Chondroitin sulfate; Elastase; Glycosaminoglycans

Indexed keywords

CHONDROITIN SULFATE; ELASTASE; ELASTASE INHIBITOR; GLYCOSAMINOGLYCAN;

ARTICLE; CONTROLLED STUDY; ENZYME INHIBITION; HUMAN; HUMAN CELL; LEUKOCYTE; STRUCTURE ACTIVITY RELATION;

ANIMALS; ANTICOAGULANTS; CHONDROITIN LYASES; CHONDROITIN SULFATES; CHROMATOGRAPHY, ION EXCHANGE; CHROMOGENIC COMPOUNDS; DISACCHARIDES; ENZYME INHIBITORS; HUMANS; LEUKOCYTE ELASTASE; MOLECULAR STRUCTURE; MOLECULAR WEIGHT; OLIGOPEPTIDES; SHARKS; STRUCTURE-ACTIVITY RELATIONSHIP; SULFATES;

EID: 0031214320     PISSN: 00092797     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0009-2797(97)00045-8     Document Type: Article

References (25)

1. [1] P.M. Starkey, A.J. Barret, M.C. Burleigh, The degradation of articular collagen by neutrophil proteinases, Biochim. Biophys. Acta 483 (1977) 386-397.
2. [2] H.B. Jovanovitch, Pulmonary emphysema and proteolysis, Academic Press, New York, 1987.
3. [3] K. Marossy, Interaction of the chymotrypsin- and elastase-like enzymes of the human granulocyte with glycosaminoglycans, Biochim. Biophys. Acta 659 (1981) 351-361.
4. [4] N. Volpi, Inhibition of human leukocyte elastase activity by heparins: influence of charge density. Biochim. Biophys. Acta 1290 (1996) 299-307.
5. [5] A. Baici, P. Bradamante, Interaction between human leukocyte elastase and chondroitin sulfate, Chem.-Biol. Interact. 51 (1984) 1-11.
6. [6] E. Paroli, Glycosaminoglycan chondroprotection: pharmacological vistas, Int. J. Clin. Pharm. Res. XIII (1993) 1-9.
7. [7] M. Adam, M. Krabkova, J. Musilova, V. Pesakova, I. Brettschneider, L.Z. Dey, Contribution to the mode of action of glycosaminoglycan polysulfate (GAGPS) upon human osteoarthritic cartilage, Arzneim. Forsch. 30 (1980) 1730-1732.
8. [8] J. Vacha, V. Pesakova, J. Krajichova, M. Adam, Effect of glycosaminoglycan polysulfate on the metabolism of cartilage ribonucleic acid, Arzneim. Forsch. 34 (1984) 607-609.
9. [9] G. Rovetta, Galactosaminoglycuronoglycan sulfate (matrix) in therapy of tibiofibular osteoarthritis of the knee. Drugs Exp. Clin. Res. XVII (1991) 53-57.
10. [10] A. Baici, C. Diczhazi, A. Neszmelyi, E. Moczar, W. Hornebeck, Inhibition of the human leukocyte endopeptidases elastase and cathepsin G and of porcine pancreatic elastase by N-oleoyl derivatives of heparin, Biochem. Pharm. 46 (1993) 1545-1549.
11. [11] L. Palmieri, A. Conte, L. Giovannini, P. Lualdi, G. Ronca, Metabolic fate of exogenous chondroitin sulfate in the experimental animal, Arzneim. Forsch. 40 (1990) 319-323.
12. [12] A. Conte, N. Volpi, L. Palmieri, I. Bahous, G. Ronca, Biochemical and pharmacokinetic aspects of oral treatment with chondroitin sulfate, Arzneim. Forsch. 45 (1995) 918-925.
13. [13] N. Volpi, Characterization of heparins with different relative molecular masses (from 11 600 to 1600) by various analytical techniques, J. Chromatogr. Biomed. Appl. 622 (1993) 1320.
14. [14] N. Volpi, L. Bolognani, Glycosaminoglycans and proteins: different behaviours in high-performance size-exclusion chromatography, J. Chromatogr. 630 (1993) 390-396.
15. [15] J.M. Thomson, L. Poller, Blood coagulation and haemostasis, in: Thomson J.M. (Ed.), Churchill Livingstone, Edinburgh, 1985.
16. [16] R.L. Walsh, T.J. Dillon, R. Scicchitano, G. Mclennan, Heparin and heparan sulphate are inhibitors of human leucocyte elasiase, Clin. Sci. 81 (1991) 341-346.
17. [17] N. Volpi, Activity of chondroitin ABC lyase and hyaluronidase on free-radical degraded chondroitin sulfate, Carbohydr. Res. 279 (1995) 193-200.
18. [18] M.F. Scully, V. Ellis, N. Seno, V.V. Kakkar, Effect of oversulphated chondroitin and dermatan sulphate upon thrombin and factor Xa inactivation by antithrombin III or heparin cofactor II, Biochem. J. 254 (1988) 547-551.
19. [19] F. Dol, C. Caranobe, D. Dupouy, M. Pelitou, J.C. Lormeau, J. Choay, P. Sie, B. Boneu. Effects of increased sulfation of dermatan sulfate on its in vitro and in vivo pharmacological properties, Thromb. Res. 52 (1988) 153-164.
20. [20] C. Bartolucci, L. Cellai, M.A Iannelli, D. Lamba, L. Liverani, G. Mascellani, E. Perola, Inhibition of human leukocyte elastase by chemically and naturally oversulfated galactosaminoglycans, Carbohydr. Res. 276 (1995) 401-408.
21. [21] D.A. Lane, I. Bjork, U. Lindahl, Heparin and related polysaccharides. Advances in experimental medicine and biology, Vol. 313, Plenum Press, New York, 1992.
22. [22] N. Volpi, R. Fregni, T. Venturelli. Activity of chondroitin ABC lyase on dermatan sulfate partially degraded by cupric-ion-mediated free-radical treatment, J. Chromatogr. Biomed. Appl. 669 (1995) 197-205.
23. [23] G.L. Bergonzini, P. Bianchini, G. Mascellani, B. Osima, B. Parma, N. Volpi, Different pharmacokinetics, antithrombotic activity and bleeding effects of heparin and two new fragments administered in rat by subcutaneous route. Arzneim. Forsch. 42 (1992) 1322-1328.
24. [24] S. Saivin, F. Dol, C. Caranobe, M. Petitou, J.C. Lormeau. P. Sie, G. Houin, B. Boncu. Influence of molecular weight upon the anticoagulant and pharmacokinetic properties of dermatan sulfate in the rabbit, Thromb. Res. 66 (1992) 527-535.
25. [25] G. Ronca, A. Conte, Metabolic late of partially depolymerized shark chondroitin sulfate in man. Int. J. Clin. Pharm. Res. XIII (1993) 27-34.